Cargando…
Cortactin expression predicts poor survival in laryngeal carcinoma
Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266851/ https://www.ncbi.nlm.nih.gov/pubmed/18268491 http://dx.doi.org/10.1038/sj.bjc.6604246 |
_version_ | 1782151571891552256 |
---|---|
author | Gibcus, J H Mastik, M F Menkema, L de Bock, G H Kluin, Ph M Schuuring, Ed van der Wal, J E |
author_facet | Gibcus, J H Mastik, M F Menkema, L de Bock, G H Kluin, Ph M Schuuring, Ed van der Wal, J E |
author_sort | Gibcus, J H |
collection | PubMed |
description | Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes including cyclin D1 and cortactin. Recently, we reported that FADD becomes overexpressed upon amplification and that FADD protein expression predicts for lymph node positivity and disease-specific mortality. However, the gene within the 11q13.3 amplicon responsible for this correlation is yet to be identified. In this paper, we compared, using immunohistochemical analysis for cyclin D1, FADD and cortactin in a series of 106 laryngeal carcinomas which gene correlates best with lymph node metastases and increased disease-specific mortality. Univariate Cox regression analysis revealed that high expression of cyclin D1 (P=0.016), FADD (P=0.003) and cortactin (P=0.0006) predict for increased risk to disease-specific mortality. Multivariate Cox analysis revealed that only high cortactin expression correlates with disease-specific mortality independent of cyclin D1 and/or FADD. Of genes located in the 11q13 amplicon, cortactin expression is the best predictor for shorter disease-specific survival in late stage laryngeal carcinomas. |
format | Text |
id | pubmed-2266851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22668512009-09-10 Cortactin expression predicts poor survival in laryngeal carcinoma Gibcus, J H Mastik, M F Menkema, L de Bock, G H Kluin, Ph M Schuuring, Ed van der Wal, J E Br J Cancer Molecular Diagnostics Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region (HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival. The 11q13.3 amplicon carries numerous genes including cyclin D1 and cortactin. Recently, we reported that FADD becomes overexpressed upon amplification and that FADD protein expression predicts for lymph node positivity and disease-specific mortality. However, the gene within the 11q13.3 amplicon responsible for this correlation is yet to be identified. In this paper, we compared, using immunohistochemical analysis for cyclin D1, FADD and cortactin in a series of 106 laryngeal carcinomas which gene correlates best with lymph node metastases and increased disease-specific mortality. Univariate Cox regression analysis revealed that high expression of cyclin D1 (P=0.016), FADD (P=0.003) and cortactin (P=0.0006) predict for increased risk to disease-specific mortality. Multivariate Cox analysis revealed that only high cortactin expression correlates with disease-specific mortality independent of cyclin D1 and/or FADD. Of genes located in the 11q13 amplicon, cortactin expression is the best predictor for shorter disease-specific survival in late stage laryngeal carcinomas. Nature Publishing Group 2008-03-11 2008-02-12 /pmc/articles/PMC2266851/ /pubmed/18268491 http://dx.doi.org/10.1038/sj.bjc.6604246 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Gibcus, J H Mastik, M F Menkema, L de Bock, G H Kluin, Ph M Schuuring, Ed van der Wal, J E Cortactin expression predicts poor survival in laryngeal carcinoma |
title | Cortactin expression predicts poor survival in laryngeal carcinoma |
title_full | Cortactin expression predicts poor survival in laryngeal carcinoma |
title_fullStr | Cortactin expression predicts poor survival in laryngeal carcinoma |
title_full_unstemmed | Cortactin expression predicts poor survival in laryngeal carcinoma |
title_short | Cortactin expression predicts poor survival in laryngeal carcinoma |
title_sort | cortactin expression predicts poor survival in laryngeal carcinoma |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266851/ https://www.ncbi.nlm.nih.gov/pubmed/18268491 http://dx.doi.org/10.1038/sj.bjc.6604246 |
work_keys_str_mv | AT gibcusjh cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT mastikmf cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT menkemal cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT debockgh cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT kluinphm cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT schuuringed cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma AT vanderwalje cortactinexpressionpredictspoorsurvivalinlaryngealcarcinoma |